A Wild CAR-T Race In China: The Hype, Reality And What Works
As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.
You may also be interested in...
New draft guidelines could potentially create parallel clinical pathways for cell and gene therapies in China, and industry executives are worried about different standards for such emerging treatments in a country with the highest number of ongoing cell therapy trials in the world.
A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.
China is overtaking the US as the largest cell development market, with over 2,300 registered clinical trials.